China Approves Hengrui ANGPTL3 Antibody for HoFH

China approved Hengrui’s subcutaneous ANGPTL3 antibody revocimab (SHR-1918) for LDL-cholesterol lowering in adults and adolescents aged at least 12 with homozygous familial hypercholesterolemia, in combination with diet and other lipid-lowering therapy. This is a…




